Grace Therapeutics GRCE
NASDAQ GRCE
$1.97 -0.01 (-0.51%)
At close: Oct 21, 2026 · 4:00 PM EDT

Grace Therapeutics (GRCE) Share-based Compensation (2019 - 2026)

Updated

Grace Therapeutics' Share-based Compensation was $105,000 in fiscal Q1 2027 (quarter ended Jun 30, 2026), down 65.2% from $302,000 a year earlier and down 42.3% from the prior quarter.

Analysis

Grace Therapeutics (GRCE) Share-based Compensation (2019 - 2026) Analysis & Trends

On a trailing twelve-month basis, Grace Therapeutics' Share-based Compensation was $601,000 through Jun 30, 2026, down 24.3% year-over-year; for FY2026 (ended Mar 31, 2026), it came in at $798,000, up 9.3% from FY2025.

  • Share-based Compensation shows a five-year compound annual growth rate of -7.4% (FY2021 to FY2026).
  • In earlier fiscal years, Share-based Compensation was $730,000 in FY2025 (-20.0%), $913,000 in FY2024 (-49.6%), $1.81 million in FY2023 (+35.5%) and $1.34 million in FY2022 (+13.9%).
  • The fiscal Q1 2027 figure marks the lowest quarterly Share-based Compensation since fiscal Q1 2024.
  • Compared with a year earlier, Share-based Compensation was higher in three of the last eight quarters, with an average decline of 18.9%.
  • The best year-over-year quarter for Share-based Compensation over five years was fiscal Q2 2023 (growth of 410.5%); the worst was fiscal Q1 2024 (a decline of 83.2%).
  • Per Business Quant data, GRCE's Share-based Compensation in the three fiscal quarters before Q1 2027 was $182,000 (Q4 2026), $108,000 (Q3 2026) and $206,000 (Q2 2026).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Stock Comp. (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 201.00 Mn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 458.00 Mn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 166.00 Mn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 298.00 Mn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn -
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn -
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 165.00 Mn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 231.00 Mn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 249.00 Mn
10 Grace Therapeutics 34.02 Mn -32.25 Mn - 105,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 105,000.00
Mar 31, 2026 182,000.00
Dec 31, 2025 108,000.00
Sep 30, 2025 206,000.00
Jun 30, 2025 302,000.00
Mar 31, 2025 130,000.00
Dec 31, 2024 160,000.00
Sep 30, 2024 202,000.00
Jun 30, 2024 238,000.00
Mar 31, 2024 229,000.00
Dec 31, 2023 326,000.00
Sep 30, 2023 280,000.00
Jun 30, 2023 78,000.00
Mar 31, 2023 322,000.00
Dec 31, 2022 443.00
Sep 30, 2022 582.00
Jun 30, 2022 464,000.00
Mar 31, 2022 616,000.00
Dec 31, 2021 454,000.00
Sep 30, 2021 114,000.00
API Access

Grace Therapeutics Share-based Compensation API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=share-based-compensation&ticker=GRCE&period=max&api_key=YOUR_API_KEY